Angiotech tests novel central venous catheters anti-infective coating
This article was originally published in Clinica
Executive Summary
Angiotech Pharmaceuticals has begun a US pivotal study to assess an anti-microbial central venous catheter (CVC) that is coated with what the firm describes as a non-traditional anti-infective agent, 5-flourouracil (5-FU).